Denosumab

Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancer

LeVee A, Peluso E, Lechner MG, Ruel N, Mortimer J, Kang I, Tsai K. Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in[...]

By afschroeder • June 25, 2025

Polypharmacy in Osteoporosis Treatment

McConnell M, Shieh A. Polypharmacy in Osteoporosis Treatment. Clin Geriatr Med. 2022 Nov;38(4):715-726. doi: 10.1016/j.cger.2022.05.011. Epub 2022 Sep 13. PMID: 36210087.

By sjmartinez • October 12, 2022